62085-80-7Relevant academic research and scientific papers
Asymmetric Transfer Hydrogenation of Arylidene-Substituted Chromanones and Tetralones Catalyzed by Noyori-Ikariya Ru(II) Complexes: One-Pot Reduction of C═C and C═O bonds
Caleffi, Guilherme S.,Brum, Juliana De O. C.,Costa, Angela T.,Domingos, Jorge L. O.,Costa, Paulo R. R.
supporting information, p. 4849 - 4858 (2021/04/06)
3-Arylidenechroman-4-ones and 2-arylidene-1-tetralones are hydrogenated to cis-benzylic alcohols in dr's and er's up to 99:1 via a C═C and C═O one-pot reduction in the presence of 2-5 mol % Noyori-Ikariya-type RuII chiral complexes and HCO2Na as a hydroge
NNN pincer Ru(II)-complex-catalyzed α-alkylation of ketones with alcohols
Cao, Xiao-Niu,Wan, Xiao-Min,Yang, Fa-Liu,Li, Ke,Hao, Xin-Qi,Shao, Tian,Zhu, Xinju,Song, Mao-Ping
, p. 3657 - 3668 (2018/04/14)
A series of novel ruthenium(II) complexes supported by a symmetrical NNN ligand were prepared and fully characterized. These complexes exhibited good performance in transfer hydrogenation to form new C-C bonds using alcohols as the alkylating agents, generating water as the only byproduct. A broad range of substrates, including (hetero)aryl- or alkyl-ketones and alcohols, were well tolerated under the optimized conditions. Notably, α-substituted methylene ketones were also investigated, which afforded α-branched steric hindrance products. A potential application of α-alkylation of methylene acetone to synthesize donepezil was demonstrated, which provided the desired product in 83% yield. Finally, this catalytic system could be applied to a one-pot double alkylation procedure with sequential addition of two different alcohols. The current protocol is featured with several characteristics, including a broad substrate scope, low catalyst (0.50 mol %) loadings, and environmental benignity.
Organocatalyzed enantioselective protonation of silyl enol ethers: Scope, limitations, and application to the preparation of enantioenriched homoisoflavones
Poisson, Thomas,Gembus, Vincent,Dalla, Vincent,Oudeyer, Sylvain,Levacher, Vincent
supporting information; experimental part, p. 7704 - 7716 (2010/12/29)
In the present work, enantioselective protonation of silyl enol ethers is reported by means of a variety of chiral nitrogen bases as catalysts, mainly derived from cinchona alkaloids, in the presence of various protic nucleophiles as proton source. A detailed study of the most relevant reaction parameters is disclosed allowing high enantioselectivities of up to 92% ee with excellent yields to be achieved under mild and eco-friendly conditions. The synthetic utility of this organocatalytic protonation was demonstrated during the preparation of two homoisoflavones 4a and 4b, isolated from Chlorophytum Inornatum and Scilla Nervosa, which were obtained with 81% and 78% ee, respectively.
Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4 (LTB4) antagonists
-
, (2008/06/13)
PCT No. PCT/IB95/00401 Sec. 371 Date Apr. 9, 1997 Sec. 102(e) Date Apr. 9, 1997 PCT Filed May 26, 1995 PCT Pub. No. WO96/11920 PCT Pub. Date Apr. 25, 1996This invention relates to novel benzopyran and other benzo-fused leukotriene B4 (LTB4) antagonists and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing such compounds or a pharmaceutically acceptable salt thereof, and to methods of using such compounds as LTB4 antagonists. The compounds and the pharmaceutically acceptable salts of this invention inhibit the action of LTB4 and are therefore useful in the treatment of LTB4 induced illnesses such as inflammatory disorders including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, psoriasis and other skin disorders such as eczema, erythema, pruritus and acne, stroke and other forms of reperfuslon injury, graft rejection, autoimmune diseases, asthma, and other conditions where marked neutrophil infiltration occurs.
Tetrahydronaphthalene and tetrahydroquinoline compounds, their preparation and their use as leukotriene B4(LTB4) antagonists
-
, (2008/06/13)
This invention relates to novel benzopyran and other benzo-fused leukotriene B4 (LTB4) antagonists and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing such compounds or a pharmaceutically acceptable salt thereof, and to methods of using such compounds as LTB4 antagonists. The compounds and the pharmaceutically acceptable salts of this invention inhibit the action of LTB4 and are therefore useful in the treatment of LTB4 induced illnesses such as inflammatory disorders including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, psoriasis and other skin disorders such as eczema, erythema, pruritus and acne, stroke and other forms of reperfusion injury, graft rejection, autoimmune diseases, asthma, and other conditions where marked neutrophil infiltration occurs.
Studies in Antifertility Agents: Part XXVIII-1,2-trans-1-(p-(&β-Pyrrolidinoethoxy)phenyl)-2-substituted-benzyl-6-methoxy-1,2,3,4-tetrahydronaphthalenes
Tewari, S. C.,Rastogi, Shri Nivas
, p. 1060 - 1064 (2007/10/02)
Substituted 2-benzyl-6-methoxy-1-tetralones (8-10), obtained by catalytic hydrogenation of 2-arylidene-1-tetralones (5-7), on NaBH4 reduction give a mixture of 1,2-trans-/cis-isomers of 2-benzyl-1-tetralols (11-13).Ac2O-pyridine treatment of 11 furnishes
